iNeu™ Human Hippocampal Spheroid

Description

The hippocampus is important for memory formation and is severely affected in the brain of Alzheimer's disease (AD). When used in AD models, both APP and the atypical PS1 variant HS showed increased Aβ42/Aβ40 peptide ratio and decreased synaptic protein levels, which are common features of AD. However, these two variants differ in terms of tau hyperphosphorylation, protein aggregation and protein network changes. NeuroD1-mediated gene therapy in HSD-derived progenitor cells can regulate the expression of many genes, including genes related to synaptic transmission. Therefore, HS can be used to reveal the underlying mechanism of early pathogenic changes in the hippocampus of AD patients and provide a powerful platform for the development of treatment strategies for early AD.

Creative Biolabs's Human iPSC-Derived Hippocampal Spheroids are derived from induced pluripotent stem cells (iPSC) without integration under fully defined neural induction conditions.

Creative Biolabs's Human iPSC-Derived Hippocampal Spheroids are rich in hippocampal neurons and express zinc finger and BTB domain-containing protein 20 (ZBTB20) and Prospero homeobox protein 1 (PROX1). In addition, the hippocampal neurons derived from the APP variant HS exhibit profound transcriptome changes, which can be regulated by the overexpression of NeuroD1 (ND1), leading to the upregulation of genes whose gene products are related to synaptic transmission and are altered in AD.

Cell Types

Hippocampal Neuron; Spheroid

Applications

High Throughput Screening

Application Notes

1.hiPSC-derived HSs can be utilized as a source of hippocampal neurons
2.hiPSC-derived HSs can be used to model Alzheimer disease
3.hiPSC-derived HSs can be used to develop innovative therapeutic solutions

Relevant Diseases

Alzheimer's Disease

Species

Human

Cell Purity

>95%

Cell Viability

>90%

Mycoplasma Testing

The cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.

Sterility Testing

Sterility testing was performed in accordance with USP and EP regulations. All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.

Genetic Stability Testing

Cell genetic stability study was perfomed under ICH guidelines. We provide guidance on the appropriate testing program upon your requirements.

Handling Advice

Frozen cells:Upon receipt, frozen ampoules should be transferred directly to gaseous phase liquid nitrogen without delay, unless they are to be used straight away.

Growing cells: Growing cell cultures should be checked on receipt using an inverted microscope. Immediately check the cell density upon arrival for any obvious defects. If the cell density is too high (more than 80% confluent) subculture the cells (harvest and reseed) immediately.

For detailed instructions on the thawing procedure of frozen cells and the culture of adherent or suspended cells, please feel free to contact us by email or phone.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Warnings

Store under recommended storage conditions (liquid nitrogen). Do not expose to high temperature. After expiration, discard all remaining reagents. It is recommended to use cells within ten generations.

Quality Control

Each batch of cells has passed the high-level expression of Nestin and Sox 2 as well as its self-renewal and multi-lineage differentiation ability. The cells also showed normal karyotypes, and mycoplasma tests were negative by chromosome spread assessment. The blood of pregnant women has been screened for HIV, HTLV, hepatitis B and C.

Pomeshchik, Y., Klementieva, O., Gil, J., Martinsson, I., Hansen, M. G., de Vries, T., ... & Roybon, L. (2020). Human iPSC-Derived Hippocampal Spheroids: An Innovative Tool for Stratifying Alzheimer Disease Patient-Specific Cellular Phenotypes and Developing Therapies. Stem cell reports, 15(1), 256-273.